These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 21223988)
1. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. Tagami T; Uehara Y; Moriyoshi N; Ishida T; Kiwada H J Control Release; 2011 Apr; 151(2):149-54. PubMed ID: 21223988 [TBL] [Abstract][Full Text] [Related]
2. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. Tagami T; Nakamura K; Shimizu T; Ishida T; Kiwada H J Control Release; 2009 Aug; 137(3):234-40. PubMed ID: 19361546 [TBL] [Abstract][Full Text] [Related]
3. B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice. Hashimoto Y; Abu Lila AS; Shimizu T; Ishida T; Kiwada H J Control Release; 2014 Jun; 184():1-8. PubMed ID: 24727075 [TBL] [Abstract][Full Text] [Related]
4. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. Wang X; Ishida T; Kiwada H J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838 [TBL] [Abstract][Full Text] [Related]
5. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery. Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762 [TBL] [Abstract][Full Text] [Related]
6. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. Ishida T; Wang X; Shimizu T; Nawata K; Kiwada H J Control Release; 2007 Oct; 122(3):349-55. PubMed ID: 17610982 [TBL] [Abstract][Full Text] [Related]
7. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. Tagami T; Nakamura K; Shimizu T; Yamazaki N; Ishida T; Kiwada H J Control Release; 2010 Mar; 142(2):160-6. PubMed ID: 19850094 [TBL] [Abstract][Full Text] [Related]
8. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Ishida T; Kiwada H Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313 [TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293 [TBL] [Abstract][Full Text] [Related]
10. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]
11. Anti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery. Abu Lila AS; Ishida T Methods Mol Biol; 2019; 1943():333-346. PubMed ID: 30838627 [TBL] [Abstract][Full Text] [Related]
12. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. Ishida T; Ichihara M; Wang X; Yamamoto K; Kimura J; Majima E; Kiwada H J Control Release; 2006 May; 112(1):15-25. PubMed ID: 16515818 [TBL] [Abstract][Full Text] [Related]
13. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Shimizu T; Ishida T; Kiwada H Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937 [TBL] [Abstract][Full Text] [Related]
14. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes. Buyens K; Demeester J; De Smedt SS; Sanders NN Langmuir; 2009 May; 25(9):4886-91. PubMed ID: 19341292 [TBL] [Abstract][Full Text] [Related]
15. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128 [TBL] [Abstract][Full Text] [Related]
16. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285 [TBL] [Abstract][Full Text] [Related]
17. Peritoneal B Cells Play a Role in the Production of Anti-polyethylene Glycol (PEG) IgM against Intravenously Injected siRNA-PEGylated Liposome Complexes. Shimizu T; Lila ASA; Kitayama Y; Abe R; Takata H; Ando H; Ishima Y; Ishida T Biol Pharm Bull; 2024; 47(2):469-477. PubMed ID: 38383000 [TBL] [Abstract][Full Text] [Related]
18. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery. Abu Lila AS; Uehara Y; Ishida T; Kiwada H J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396 [TBL] [Abstract][Full Text] [Related]
19. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein. Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445 [TBL] [Abstract][Full Text] [Related]
20. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. Ishida T; Ichihara M; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]